Table 1 Summary of the chosen Infliximab peptides with their corresponding precursor and product m/z values and their optimized collision energy
Peptide sequence | Precursor (m/z) | Product (m/z) | Opt. CE (V) |
|---|---|---|---|
SINSATHYAESVK(+ 3) | 469.568 | 467.735 | 5.4 |
SINSATHYAESVK(+ 3) | 469.568 | 503.254 | 9.4 |
SINSATHYAESVK(+ 3) | 469.568 | 546.77 | 8.4 |
SINSATHYAESVK(+ 3) | 469.568 | 603.791 | 7.4 |
SINSATHYAESVK(+ 3) | 469.568 | 696.356 | 15.4 |
SINSATHYAESVK (heavy)(+ 3) | 472.239 | 471.742 | 5.4 |
SINSATHYAESVK (heavy)(+ 3) | 472.239 | 507.261 | 9.4 |
SINSATHYAESVK (heavy)(+ 3) | 472.239 | 550.777 | 8.4 |
SINSATHYAESVK (heavy)(+ 3) | 472.239 | 607.798 | 7.4 |
SINSATHYAESVK (heavy)(+ 3) | 472.239 | 704.37 | 15.4 |
ASQFVGSSIHWYQQR(+ 3) | 598.628 | 631.307 | 9.2 |
ASQFVGSSIHWYQQR(+ 3) | 598.628 | 680.841 | 11.2 |
ASQFVGSSIHWYQQR(+ 3) | 598.628 | 754.376 | 10.2 |
ASQFVGSSIHWYQQR(+ 3) | 598.628 | 780.379 | 19.2 |
ASQFVGSSIHWYQQR(+ 3) | 598.628 | 917.438 | 20.2 |
ASQFVGSSIHWYQQR (heavy)(+ 3) | 601.964 | 636.311 | 9.2 |
ASQFVGSSIHWYQQR (heavy)(+ 3) | 601.964 | 685.846 | 11.2 |
ASQFVGSSIHWYQQR (heavy)(+ 3) | 601.964 | 759.38 | 10.2 |
ASQFVGSSIHWYQQR (heavy)(+ 3) | 601.964 | 790.387 | 19.2 |
ASQFVGSSIHWYQQR (heavy)(+ 3) | 601.964 | 927.446 | 20.2 |